The management of the infected diabetic foot

Current Diabetes Reviews

Volumn 9, Issue 1, 2013, Pages 7-24

  Caravaggi, Carlo ^a,d   Sganzaroli, Adriana ^a   Galenda, Paolo ^a   Bassetti, Matteo ^b   Ferraresi, Roberto ^a   Gabrielli, Livio ^c  

^a ISTITUTO CLINICO CITTÀ STUDI   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Charcot neuroarthropaty; Diabetic foot; Diabetic foot infection; Diabetic foot surgery; Diabetic foot ulcer; Ischemic diabetic foot

Indexed keywords

ACETYLSALICYLIC ACID; CEFTRIAXONE; CIPROFLOXACIN; CLOPIDOGREL; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLITEF; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BYPASS SURGERY; COMPARTMENT SYNDROME; DEBRIDEMENT; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC PERIPHERAL NEUROPATHY; DISEASE SEVERITY; FOOT AMPUTATION; GANGRENE; GRAFT PATENCY; GRAM NEGATIVE INFECTION; HUMAN; LEG AMPUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NECROTIZING FASCIITIS; OSTEOMYELITIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHLEGMON; PLASTIC SURGERY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECANALIZATION; REVASCULARIZATION; SURGERY; TREATMENT DURATION; WOUND ASSESSMENT; WOUND INFECTION;

EID: 84875919222     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339913804143216     Document Type: Article

References (112)

1. World Health Org. Fact sheet N°312, August 2011 www.who.int/mediacentre/factsheets/fs/312/en/
2. Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 336: 1719-1724.
3. Johannesson A, Larsson GU, Ramstrand N, Turkiewicz A, Wirehn AAtroshi Incidence of lower-limb amputation in the Diabetic e Non diabetic general population. A 10-year population-based cohort study of initial unilateral and contralateral amputation and reamputation Diabetes Care February 2009; Vol. 32 no.2: 275-280.
4. International Working Group on the Diabetic Foot. International consensus on the diabetic foot. 2011. In: International Diabetes Foundation; Brussels. http://www.iwgdf.org
5. Jeffcoate WJ, van Houtum WH. Amputation as a marker of the quality of foot care in diabetes. Diabetologia 2004; 47: 2051-2058.
6. Boulton AJM, Armstrong DG, Albert FA, et al. Comprehensive foot examination and risk assessment. Diabetes Care 2008; 31: 1679-1685.
7. Prompers, L, Shaper N, Apelquist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008; 51: 747.
8. Andreassen CS, Jakobsen J, Andersen H. Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes 2006; 55: 806-812.
9. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJM. Predictive value of foot pressure assessment as part of a population-based diabetes disease management program. Diabetes Care 2003; 26: 1069-1073.
10. Greenman RL, Panasyuk S, Wang X, et al. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. Lancet 2005; 366: 1711-1717.
11. Litzelman DK, Marriott DJ, Vinicor F. Independent physiological predictors of foot lesions in patients with NIDDM. Diabetes Care 1997; 20: 1273-1278.
12. Macfarlane RM, Jeffcoate WJ. Factors contributing to the presentation of diabetic foot ulcers. Diabet Med 1997; 14: 867-870.
13. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162.
14. Armstrong DG, Todd WF, Harkless LB, Bushman TR. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 1997; 14: 357-363.
15. Schon LC, Easley ME, Weinfeld SB. Charcot neuroarthropathy of the foot and ankle. Clin Orthop 1998; 349: 116-131.
16. Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. In: Levin ME, O'Neal LW, U Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002; 45: 1085-1096.
17. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50: 18-25.
18. Norgren L, Hiatt WR, Dormandy JA, et al. On behalf of the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: S5-S67.
19. Faglia E, Clerici G, Caminiti M, Quarantiello A, Curci V, Somalvico F. Evaluation of Feasibility of Ankle Pressure and Foot Oxymetry Values for the Detection of Critical Limb Ischemia in Diabetic Patients. Vascular and Endovascular Surgery 2010; 44 (3): 184-189.
20. Faglia E, Clerici G, Caminiti M, Quarantiello A, Curci V, Morabito A. Predictive values of transcutaneous oxygen tension for abovethe- ankle amputation in diabetic patients with critical limb ischemia. Eur J Vasc Endovasc Surg 2007; 33: 731-736.
21. Shah B, Hux J. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510-513.
22. Sato N, Shimizu H, Susa K, Shimomura Y, Kobayashi I, Mori M. MPO activity and generation of active O2 species in leukocytes from poorly controlled diabetic patients. Diabetes Care 1992; 15: 1050-1052.
23. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15: 256-260.
24. Muchová J, Liptáková A, Országhová Z, et al. Antioxydant system in polymorphonuclear leucocytes of type 2 diabetes mellitus. Diabet Med 1999; 16: 74-78.
25. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.
26. Shone A, Burnside J, Chipchase S, Game F, Jeffcoate W. Probing the validity of the probe-to-bone test in the diagnosis of osteomyelitis of the foot in diabetes. Diabetes Care 2006; 29: 945.
27. Delcourt A, Huglo D, Prangere T, et al. Comparison between Leukoscan (Sulesomab) and Gallium-67 for the diagnosis of osteomyelitis in the diabetic foot. Diabetes Metab 2005; 31: 125-133.
28. Maugendre D, Poirier JY. Nuclear medicine in the diagnosis of diabetic foot osteomyelitis. Diabetes Metab 2001; 27: 396-400.
29. Poirier JY, Garin E, Derrien C, Devillers A, Moisan A, Bourguet P, Maugendre D. Diagnosis of osteomyelitis in the diabetic foot with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99m-Tc-MDP bone scintigraphy. Diabetes Metab 2002; 28: 485-490.
30. Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 2008; 24 Suppl 1: S145-S161.
31. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg 1996; 35: 528-531.
32. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21: 855-859.
33. Van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004; 39 Suppl 2: S123-S128.
34. Faglia E, Clerici G, Caminiti M, Quarantiello A, Gino M, Morabito A. The role of early surgical debridement and revascularization in patients with diabetes and deep foot space abscess: retrospective review of 106 patients with diabetes. J Foot Ankle Surg 2006; 45: 220-226.
35. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006; 29: 1288-1293.
36. Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale study. Diabetologia 2008; 51: 1826-1834
37. Lavery LA, Armstrong DG, Wunderlich RP, Boulton AJM, Tredwell JM. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003; 26: 1435-1438.
38. Jeffcoate WJ, Lipsky BA, Berendt AR, et al. International Working Group on the Diabetic Foot. Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 2008; 25: 1380-1389.
39. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microb and Infect Dis 2007; 57: 7-13.
40. Gagliotti C, Balode A, Baquero F, et al. EARS-Net Participants (Disease Specific Contact Points for AMR). Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011; 17: 16(11)pii: 19819.
41. Spellberg B, Guidos R, Gilbert D, et al. Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-164.
42. El Solh N, Davi M, Morvan A, Damon HA, Marty N. GISA group, RAISIN subgroup. Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides. J Antimicrob Chemother 2003; 52: 691-694
43. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hasçelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56: 519-523.
44. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006; 44: 3883-3886.
45. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram_positive bacteria. Int J Clin Pract 2008; 62: 1455-1464.
46. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43: 1211-1219.
47. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of highdose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49: 177-178.
48. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010; 36: 459-461.
49. Peterson LR. A review of tigecycline-the first glycylcycline. Int J Antimicrob Ajents 2008; 32,S4: 215-222.
50. FDA. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (1 September 2010).
51. Graziani L, Silvestro A, Bertone V, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007; 33: 453-460.
52. Jude EB, Oyibo SO, Chalmers N, Boulton AJM. Peripheral Arterial Disease in Diabetic and Nondiabetic Patients. Diabetes Care 2001; 24: 1433-1437.
53. Ferraresi R, Centola M, Ferlini M, et al. Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 2009; 37: 336-342.
54. Diehm N, Shang A, Silvestro A, et al. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg 2006; 31: 59-63.
55. Peregrin JH, Koznar B, Kovác J, Lastovicková J, Novotn- J, Vedlich D, Skibová J. PTA of infrapopliteal arteries: long-term clinical follow-up and analysis of factors influencing clinical outcome. Cardiovasc Intervent Radiol 2010; 33: 720-725.
56. Faglia E, Clerici G, Clerissi J. et al. When is a technically successful peripheral angioplasty effective in preventing above-the-ankle amputation in diabetic patients with critical limb ischaemia? Diabetic Med 2007; 24; 823-829.
57. Attinger CE, Evans KK, Bulan E, Blume P, Cooper P. Angiosomes of the foot and ankle and clinical implications for limb salvage: reconstruction, incisions, and revascularization. Plast Reconstr Surg 2006; 117: 261S-293S
58. Iida O, Nanto S, Uematsu M, et al. Importance of the angiosome concept for endovascular therapy in patients with critical limb ischemia. Catheter Cardiovasc Interv 2010; 75: 830-836.
59. Alexandrescu V, Vincent G, Azdad K, et al. A reliable approach to diabetic neuroischemic foot wounds: below-the-knee angiosomeoriented angioplasty. J Endovasc Ther 2011; 18: 376-387.
60. Neville RF, Attinger CE, Bulan EJ, Ducic I, Thomassen M, Sidawy AN. Revascularization of a specific angiosome for limb salvage: does the target artery matter? Ann Vasc Surg 2009; 23: 367-373.
61. International consensus on the diabetic foot and practical guidelines on the managenet and prevention of the diabetic foot. A Systematic Review of the Effectiveness of Revascularisation of the Ulcerated Foot in Patients with Diabetes and Peripheral Arterial Disease. International working group on the diabetic foot. 6th International Symposium on the Diabetic Foot (ISDF). 11-14 May 2011, Noordwijkerhout, The Netehrlands.
62. Aulivola B, Pomposelli FB. Dorsalis pedis, tarsal and plantar artery bypass. J Cardiovasc Surg 2004; 45: 203.
63. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M, Campbell DR. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. J Vasc Surg 2003; 37: 307.
64. Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation 2001; 104: 2057-2062.
65. Nasr MK, McCarthy RJ, Hardman J, Chalmers A, Horrocks M. The increasing role of percutaneous transluminal angioplasty in the primary management of critical limb ischaemia. Eur J Vasc Endovasc Surg 2002; 23: 398-403.
66. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovas Surg 2005; 29: 620-627.
67. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular 2006; 14: 63-69.
68. Tefera G, Turnipseed W, Tanke T. Limb salvage angioplasty in poor surgical candidates. Vasc Endovascular Surg 2003; 37: 99-104.
69. Jämsén T, Manninen H, Tulla H, Matsi P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J Vasc Interv Radiol 2002; 13: 455-463.
70. Tan M, Pua U, Wong DE, Punamiya SJ, Chua GC, Teo N. Critical limb ischaemia in a diabetic population from an Asian Centre: angiographic pattern of disease and 3-year limb salvage rate with percutaneous angioplasty as first line of treatment. Biomed Imaging Interv J 2010; 6: 33.
71. Uccioli L, Gandini R, Giurato L, Fabiano S, Pampana E, Spallone V, Vainieri E, Simonetti G. Long-term outcomes of diabetic patients with critical limb ischemia followed in a tertiary referral diabetic foot clinic. Diabetes Care 2010; 33: 977-982.
72. Markose G, Bolia A. Below the knee angioplasty among diabetic patients. J Cardiovasc Surg (Torino) 2009; 50: 323-329.
73. Apelqvist J, Elgzyri T, Larsson J, Löndahl M, Nyberg P, Thörne J. Factors related to outcome of neuroischemic/ischemic foot ulcer in diabetic patients. J Vasc Surg 2011; 53: 1582-1588.
74. Dick F, Diehm N, Galimanis A, Husmann M, Schmidli J, Baumgartner I. Surgical or endovascular revascularization in pa tients with critical limb ischemia: influence of diabetes mellitus on clinical outcome. J Vasc Surg 2007; 45: 751-761.
75. Eidt D, Roll S, Kulp W, et al. Bypass materials in vascular surgery. GMS Health Technol Assess. 2006 Mar 28; 2: Doc06.
76. Flu HC, Ploeg AJ, Marang-van de Mheen PJ, et al. Patient and procedure-related risk factors for adverse events after infrainguinal bypass. J Vasc Surg 2010; 51: 622-627.
77. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Pereira CA. Meta-analysis of femoro-popliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg 2006; 44: 510-517
78. Slim H, Tiwari A, Ahmed A, Ritter JC, Zayed H, Rashid H. Distal versus ultradistal bypass grafts: amputation-free survival and patency rates in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg 2011; 42: 83-88.
79. Weis-Müller BT, Römmler, V, et al. Critical Chronic Peripheral Arterial Disease: Does Outcome Justify Crural or Pedal Bypass Surgery in Patients With Advanced Age or With Comorbidities? Ann Vasc Surg 2011; 25: 783-795.
80. Watelet J, Soury P, Menard J-F, et al. Femoropopliteal bypass: in situ or reversed vein grafts? Ten-year results of a randomized prospective study. Ann Vasc Surg 1997; 11: 510-519.
81. Twine CP, McLain AD. Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev 2010; 5: CD001487.
82. Griffiths GD, Nagy J, Black D, Stonebridge PA. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoroethylene bypass grafting. Br J Surg 2004; 91: 560-562.
83. Nguyen LL, Conte MS, Menard MT, et al. Infrainguinal vein bypass graft revision: factors affecting long-term outcome. J Vasc Surg 2004; 40: 916-923.
84. Belch JJF, Dormandy J and the CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-833.
85. Nice C, Timmons G, Bartholemew P, Uberoi R. Retrograde vs. antegrade puncture for infra-inguinal angioplasty. Cardiovasc Intervent Radiol 2003; 26: 370-374.
86. Biondi-Zoccai GG, Agostoni P, Sangiorgi G, et al. Mastering the antegrade femoral artery access in patients with symptomatic lower limb ischemia: learning curve, complications, and technical tips and tricks. Catheter Cardiovasc Interv 2006; 68: 835-842.
87. Wheatley BJ, Mansour MA, Grossman PM, Chambers CM, et al. Complication rates for percutaneous lower extremity arterial antegrade access. Arch Surg 2011; 146: 432-435.
88. Bown MJ, Bolia A, Sutton AJ. Subintimal angioplasty: metaanalytical evidence of clinical utility. Eur J Vasc Endovasc Surg 2009; 38: 323-337.
89. Fusaro M, Agostoni P, Biondi-Zoccai G. "Trans-collateral" angioplasty for a challenging chronic total occlusion of the tibial vessels: a novel approach to percutaneous revascularization in critical lower limb ischemia. Catheter Cardiovasc Interv 2008; 71: 268-272.
90. Fusaro M, Dalla Paola L, Biondi-Zoccai G. Pedal-plantar loop technique for a challenging below-the-knee chronic total occlusion: a novel approach to percutaneous revascularization in critical lower limb ischemia. J Invasive Cardiol 2007; 19: 34-37.
91. Manzi M, Fusaro M, Ceccacci T, Erente G, Dalla Paola L, Brocco E. Clinical results of below-the knee intervention using pedalplantar loop technique for the revascularization of foot arteries. J Cardiovasc Surg (Torino) 2009; 50: 331-337.
92. Fusaro M, Dalla Paola L, Biondi-Zoccai GG. Retrograde posterior tibial artery access for below-the-knee percutaneous revascularization by means of sheathless approach and double wire technique. Minerva Cardioangiol 2006; 54: 773-777.
93. Zhu YQ, Zhao JG, Li MH, et al. Retrograde transdorsal-to-plantar or transplantar-to-dorsal intraluminal re-entry following unsuccessful subintimal angioplasty for below-the-ankle arterial occlusion. J Endovasc Ther 2010; 17: 712-721.
94. Marinescu V, Mirowska KK, Schreiber T, Elder M, Petrina M. Insights into endovascular revascularization in limb salvage procedures: "antegrade-retrograde" technique in chronic total occlusion. Rev Cardiovasc Med 2011; 12: 42-47.
95. Hansen A, Krawzcynski H, Lacher F. Retrograde transpedale recanalisation of tibial artery occlusion. Vasa 2009; 38: 249-253.
96. Graziani L, Silvestro A, Monge L, et al. Transluminal angioplasty of peroneal artery branches in diabetics: initial technical experience. Cardiovasc Intervent Radiol 2008; 31: 49-55.
97. Graziani L, Morelli LG. Combined retrograde-antegrade arterial recanalization through collateral vessels: redefinition of the technique for below-the-knee arteries. Cardiovasc Intervent Radiol 2011; 34 Suppl 2: S78-S82.
98. Gandini R, Pipitone V, Stefanini M, et al. The "Safari" technique to perform difficult subintimal infragenicular vessels. Cardiovasc Intervent Radiol 2007; 30: 469-473.
99. Gandini R, Volpi T, Pampana E, Uccioli L, Versaci F, Simonetti G. Applicability and clinical results of percutaneous transluminal angioplasty with a novel, long, conically shaped balloon dedicated for below-the knee interventions. J Cardiovasc Surg (Torino) 2009; 50: 365-371.
100. Peeters P, Keirse K, Verbist J, Deloose K, Bosiers M. Other endovascular methods of treating the diabetic foot. J Cardiovasc Surg (Torino) 2009; 50: 313-321.
101. Zeller T, Sixt S, Rastan A. New techniques for endovascular treatment of peripheral artery disease with focus on chronic critical limb ischemia. Vasa 2009; 38: 3-12.
102. Schmidt A, Ulrich M, Winkler B, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv 2010; 76: 1047-1054.
103. Ferraresi R. Advanced techniques for optimal interventional recanalisation in complex below the knee disease. EuroPCR, 17-20 May 2011, Paris - France.
104. Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries restenosis rate and clinical outcome. J Am Coll Cardiol 2011; 58: 1105-1109.
105. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg 2005; 41: 423-435.
106. Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008; 47: 975-981.
107. Armstrong DG, Frykberg RG. Classifying diabetic foot surgery: toward rational definition. Diabetic Medicine 2003 Ap; 2084. 329-331.
108. Caputo WJ, Beggs DJ, DeFede JL, Simm L, Dharma H. A prospective randomised controlled clinical trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. Int Wound J 2008; 5: 288-294.
109. Armstrong DG, Lavery LA. Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 12; 366(9498): 1704-1710.
110. Birke-Sorensen H, Malmsjo M, Rome P, et al. (International Expert Panel on Negative Pressure Wound Therapy [NPWT-EP]), Martin R, Smith J. Evidence-based recommendations for negative pressure wound therapy: Treatment variables (pressure levels, wound filler and contact layer) - Steps towards an international consensus. J Plast Reconstr Aesthet Surg 2011; 64 Suppl: S1-S16.
111. Espandar R, Sibdari SY, Rafiee E, Yazdanian S. Necrotizing fasciitis of the extremities: a prospective study. Strategies Trauma Limb Reconstr 2011 Nov; 6(3): 121-125.
112. Carlo Caravaggi, MD; Francesco Grigoletto, ScD; Nicolò Scuderi, MD Wound Bed Preparation With a Dermal Substitute (Hyalomatrix® PA) Facilitates Re-epithelialization and Healing: Results of a Multicenter, Prospective, Observational Study on Complex Chronic Ulcers (The FAST Study) Wounds 2011; 23(8): 228-235.